Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer

US10471160B2 · kind B2 · utility

Assignees

• Deutsches Krebsforschungszentrum · DE
• RUPRECHT - KARLS - UNIVERSITÄT HEIDELBERG · DE

Inventors

• Matthias Eder · Freiburg (Elbe), DE
• Klaus Kopka · Dossenheim, DE
• Martin SCHÄFER · Neckarsteinach, DE
• Ulrike BAUDER-WÜST · Schriesheim, DE
• Uwe Haberkorn · Schwetzingen, DE
• Michael Eisenhut · Heidelberg, DE
• Walter Mier · Bensheim, DE
• Martina Benesova · Neckarsteinach, DE
• Hans-Christian Kliem · Heppenheim, DE
• Clemens KRATOCHWIL · Hirschberg, DE

Key dates

• Filing date: Jul 18, 2018
• Grant date: Nov 12, 2019
• Expiry date: Jul 18, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D295/145
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).